Free Trial

Scinai Immunotherapeutics Q3 2023 Earnings Report

Scinai Immunotherapeutics logo
$3.40 +0.03 (+0.89%)
(As of 12/20/2024 05:16 PM ET)

Scinai Immunotherapeutics EPS Results

Actual EPS
-$6.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scinai Immunotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scinai Immunotherapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scinai Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scinai Immunotherapeutics and other key companies, straight to your email.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics (NASDAQ:SCNI), a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

View Scinai Immunotherapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings